The Triumph of Hope Over Science
By Mark Derr,
New York Times
| 02. 24. 2004
After I was diagnosed with Parkinson's disease two years ago,
at the relatively young age of 52, I read everything I could
about the condition's usual "progression" — an
odd word for degeneration. The worst-case prognosis is grim:
a long slide into physical and mental incapacity.
That is not going to happen to me, I said, as I began measuring
my physical decline. I am young enough that I may be able to
benefit from advances in medicine, especially in brain research.
Maybe with new medications I would be able to put off taking
L-dopa, the best drug for Parkinson's but one that loses its
effectiveness over time. Surely better treatments will become
available, I told myself.
So why didn't I welcome the news that researchers in South
Korea were able to clone a human embryo and extract viable stem
cells from it? After all, one of the researchers said their
goal was "not to clone humans, but to understand the causes
of diseases" — and one of the diseases named most
often was Parkinson's. Scientists say they may one...
Related Articles
By Rob Stein, NPR [cites CGS' Katie Hasson] | 08.06.2025
A Chinese scientist horrified the world in 2018 when he revealed he had secretly engineered the birth of the world's first gene-edited babies.
His work was reviled as reckless and unethical because, among other reasons, gene-editing was so new...
By Kristel Tjandra, Genetic Engineering & Biotechnology News | 07.30.2025
CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on various fronts. But getting CRISPR experiments right in the lab isn’t simple...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...